CinCor Hypertension Drug Flunks Study, But the Biotech Still Sees a Phase 3 Path
Cincor Pharma drug baxdrostat failed its Phase 2 test, falling short of the goal of reducing blood pressure in patients with uncontrolled hypertension. But results in a subgroup of patients showed double-digit declines, which the company said could inform the design of a Phase 3 clinical trial.
Source: medcitynews.com